A survey of practice in management of malignant ascites

Journal of Pain and Symptom Management

Volumn 16, Issue 2, 1998, Pages 96-101

  Lee, Christopher W ^a   Bociek, Greg ^a,b   Faught, Wylam ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Ascites; Diuretics; Mail survey; Neoplasms; Paracentesis; Peritoneovenous shunt

Indexed keywords

DIURETIC AGENT;

ADULT; ARTICLE; ASCITES; DIET THERAPY; DIURETIC THERAPY; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; NORMAL HUMAN; PALLIATIVE THERAPY; PARACENTESIS; PERITONEUM VEIN SHUNT; PHYSICIAN ATTITUDE;

ADULT; ASCITES; CANADA; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0032144098     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(98)00037-2     Document Type: Article

References (15)

1. 1. Ringenberg QS, Doll DC, Loy TS, et al. Malignant ascites of unknown origin. Cancer 1989;64: 753-755.
2. 2. Parsons SL, Watson SA, Steele RJC. Malignant ascites. Br J Surg 1996;83:6-14.
3. 3. Baker AR, Weber JS. Treatment of malignant ascites. In DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 4th ed. Philadelphia: Lippincott, 1993:2255-2261.
4. 4. Pockros PJ, Esrason KT, Nguyen C, et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992;103:1302-1306.
5. 5. Garrison RN, Kaelin LD, Galloway RH, et al. Malignant ascites. Clinical and experimental observations. Ann Surg 1986;203:644-651.
6. 6. Dillman DA. Mail and telephone surveys. New York; John Wiley and Sons, 1978:21-28.
7. 7. Ross GJ, Kessler HB, Clair MR, et al. Sonographically guided paracentesis for palliation of symptomatic malignant ascites. Am J Roentgenol 1989;153:1309-1311.
8. 8. Sharma S, Walsh D. Management of symptomatic malignant ascites with diuretics: two case reports and a review of the literature. J Pain Symptom Manage 1995;10:237-242.
9. 9. Torisu M, Katano M, Kimura Y, et al. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 1983;93:357-364.
10. 10. Lissoni P, Barni S, Tancini G, et al. Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2. Support Care Cancer 1995;3:78-80.
11. 11. Buckman R, De Angelis C, Shaw P, et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol 1992;47:102-109.
12. 12. Helzberg JH, Greenberger NJ. Peritoneovenous shunts in malignant ascites. Dig Dis Sci 1985;30: 1104-1107.
13. 13. Edney JA, Hill A, Armstrong D. Peritoneovenous shunts palliate malignant ascites. Am J Surg 1989; 158:598-601.
14. 14. Gough IR, Balderson GA. Malignant ascites: a comparison of peritoneovenous shunting and non-operative management. Cancer 1993;71:2377-2382.
15. 15. Faught W, Kirkpatrick JR, Krepart GV, et al. Peritoneovenous shunt for palliation of gynecologic malignant ascites. J Am Coll Surg 1995;180:472-474.